| Today's Top Story |  |  | | - Symphogen licenses experimental cancer drug to Merck
Merck KGaA secured exclusive worldwide development rights to Symphogen's Sym004, an anti-EGFR, dual-antibody mixture undergoing clinical trials for advanced KRAS wild-type metastatic colorectal cancer and squamous cell carcinoma of the head and neck. The licensing deal entitles Symphogen to about $25 million upfront plus as much $283 million in clinical development and regulatory milestone payments and about $314 million in potential sales milestone fees and royalties. Genetic Engineering & Biotechnology News (9/6)        | Get More with The Business Platinum Card from American Express OPEN. EARN 25,000 MEMBERSHIP REWARDS® POINTS by spending $5,000 in the first 3 months of Card membership†.
PLUS GET 40+ PREMIUM BENEFITS:
• Complimentary Airport Club Access
• Annual $200 Airline Fee Credit for any Airline
• 24/7 personal concierge
LEARN MORE †Terms and Restrictions Apply. |
  | Health Care & Policy | | | | - ImaginAb to develop imaging agents for MacroGenics
ImaginAb has entered a deal to develop imaging agents to be used in conjunction with a cancer drug being developed by MacroGenics. ImaginAb will develop agents for B7-H3, an immune regulator target that MacroGenics is using to develop the treatment. ImaginAb will also use a MacroGenics anti-CD3 antibody to develop a patient-selection tool for ongoing clinical trials. GenomeWeb Daily News (free registration) (9/5) | Company & Financial News | | | | - Zymeworks obtains $11M in financing, gets milestone pay from Merck
Zymeworks, which develops bispecific antibody drugs, raised an additional $11 million in venture capital from angel investors. The firm will use the money to develop an internal cancer drug candidate, which it hopes to bring into clinical study by late 2014. Zymeworks also received a cash payment from Merck & Co. after achieving a technical milestone linked to their collaboration. Xconomy/Seattle (9/6)
| Food & Agriculture | | | | - EU court: Member nations can't ban EU-approved biotech crops
Member nations can't block the cultivation of biotech crops approved by the European Union, the European Court of Justice ruled in a case involving Pioneer Hi-Bred Italia and the Italian agriculture ministry. A lack of policies to ensure co-existence between biotech, organic and traditional crops doesn't give a member state the right to ban biotech crops, the court said. Bloomberg (9/6) | Industrial & Environmental | | | | - Study looks at biofuel potential of nonflowering switchgrass
Introducing a gene from corn into switchgrass would inhibit its maturation, allowing it to store more starch for conversion into cellulosic ethanol, according to scientists with the USDA's Agricultural Research Service and the University of California at Berkeley. Nonflowering varieties of switchgrass could boost starch content by 250%, said Sarah Hake, an ARS geneticist. Agriculture Research Service (USDA) (9/2012)  | First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events. | | News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | The uncreative mind can spot wrong answers, but it takes a very creative mind to spot wrong questions."
--Antony Jay,
British writer, broadcaster, director and actor  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, September 06, 2012
- Wednesday, September 05, 2012
- Tuesday, September 04, 2012
- Friday, August 31, 2012
- Thursday, August 30, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment